AAP
FHTX icon

Arax Advisory Partners’s Foghorn Therapeutics FHTX Stock Holding History

Arax Advisory Partners’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-519
Closed -$2.54K – 4236
2025
Q3 		$2.54K Buy
+519
New +$2.75K ﹤0.01% 3056

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Arax Advisory Partners's FHTX Position: Q4 2025 in Review

Arax Advisory Partners sold out of Foghorn Therapeutics (FHTX) in Q4 2025, closing a stake of 519 shares — an estimated $2.54K sold.

Arax Advisory Partners first reported a position in FHTX in Q3 2025 and held it in 1 quarter. The position peaked at $2.54K in Q3 2025. 93 funds tracked by Wall St. Rank hold FHTX as of Q4 2025.

  • Arax Advisory Partners reported no remaining Foghorn Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Arax Advisory Partners sold 519 Foghorn Therapeutics shares in Q4 2025, an estimated $2.54K.
  • Arax Advisory Partners first reported a position in Foghorn Therapeutics in Q3 2025 and held it in 1 quarter.
  • Arax Advisory Partners's Foghorn Therapeutics position peaked at $2.54K in Q3 2025.
  • 93 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q4 2025.

Based on Arax Advisory Partners's 13F filing for Q4 2025, filed 13 Feb 2026.